|Bid||1,815.00 x 0|
|Ask||1,814.50 x 0|
|Day's Range||1,784.50 - 1,816.00|
|52 Week Range||1,491.50 - 2,089.00|
|Beta (3Y Monthly)||0.60|
|PE Ratio (TTM)||15.45|
|Earnings Date||Aug 9, 2019|
|Forward Dividend & Yield||0.40 (2.22%)|
|1y Target Est||23.92|
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...
Attractive stocks have exceptional fundamentals. In the case of Hikma Pharmaceuticals PLC (LON:HIK), there's is a...
Every investor in Hikma Pharmaceuticals PLC (LON:HIK) should be aware of the most powerful shareholder groups...
LONDON, May 30, 2019 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma) (HIK.L) (NASDAQ Dubai: HIK) (HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable) today announced its venture capital arm Hikma Ventures has participated in an $11 million financing round for Boston-based Pillo Health. The Series A round, led by Stanley Black & Decker's corporate venture capital arm with participation from Samsung Ventures and existing investors BioAdvance, Hackensack Meridian Health System's Innovation Center Fund and Civilization Ventures, will be used to drive growth and innovation as Pillo Health builds out its voice-enabled medication and care management platform for home use. "Our investment in Pillo Health underscores our deep commitment to developing innovative healthcare technology solutions that will put better health within reach for more patients around the world," said Lana Ghanem, Managing Director Hikma Ventures.
BOSTON, May 29, 2019 /PRNewswire/ -- Pillo Health, a Boston-based technology company improving longevity and quality of life for patients managing their health at home, today announced that is has secured $11 million in funding from leading venture investors to complete its Series-A round. The capital will be used to drive growth and innovation as Pillo Health builds out its voice-enabled medication and care management platform for the home.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Today we will run through one way of estimating the intrinsic value of Hikma Pharmaceuticals PLC (LON...
The Grand Hack is MIT Hacking Medicine's annual flagship event dedicated to energise, infect and teach healthcare entrepreneurship and digital strategies to scale medicine as a way to solve health problems worldwide. More than 500 participants, mentors and sponsors from 25 US states and 29 countries are expected to gather on campus in the MIT Media Lab for this year's Grand Hack, the largest healthcare hackathon in the US. As a strategic sponsor, Hikma and its venture capital arm Hikma Ventures will support the Grand Hack's 'Personalised Medicine' theme, which focuses on solving challenges in improving preventative medicine, treatment affordability and personalised medicine dosages. Hikma will also have representatives on-site to speak with those attendees interested in exploring opportunities to join Hikma in its mission of putting better health within reach of millions of people through its high-quality medicines and healthcare solutions.
"Vancomycin Hydrochloride for Injection is an essential antibiotic used by hospitals to treat patients who have failed to respond to a number of other antibiotics, and it's another important addition to our growing US portfolio," said Dan Motto, Executive Vice President, Commercial and Development, Injectables.
The opioid crisis in the United States is a medical and societal tragedy, but some companies are working to fight addiction.
The FTSE 100 was up 0.3 percent. The domestically-focused FTSE 250 was up 0.3 percent as investors waited for further Brexit developments with reports that Prime Minister Theresa May would ask the European Union to delay Brexit by at least three months. May's Brexit plans were derailed after the speaker of Britain's parliament said on Monday that her deal could not be voted on again after two thumping defeats unless a different proposal was submitted.
In December 2018, Hikma Pharmaceuticals PLC (LON:HIK) announced its latest earnings update, which showed that the company turned profitable again after experiencing negative earnings in the previous financial year. Below,Read More...
European shares jumped on Wednesday as investors bet British lawmakers would vote to reject a disorderly no-deal Brexit, but underwhelming results from Inditex and Adidas kept gains limited. Lawmakers resoundingly voted against Prime Minister Theresa May's amended Brexit deal late on Tuesday, forcing parliament to decide whether to back a no-deal Brexit or seek a last-minute delay to the process. "I think the market can see that today parliament is going to vote against no deal," said Duncan Weldon, cross asset allocation strategist at Legal & General Investment.
(Reuters) - Hikma Pharmaceuticals Plc on Wednesday forecast growth in 2019 for its injectable drugs division, as strong demand along with a rebound in its generics business helped it post a 19 percent ...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Small and large cap stocks are widelyRead More...
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...
Activities at upcoming ASHP conference include sponsorship of important symposium advancing patient safety practices
Postal company Royal Mail (RMG.L) is set to lose its place in the FTSE 100 (.FTSE), while insurer Hiscox (HSX.L) is likely to join Britain's top stock index in a reshuffle next week, analysts said. Demotion from the blue-chip index would come just as Royal Mail heads into its busiest time of year, as Britons send millions of greeting cards to family and friends in the run-up to Christmas. The possible swap comes after Royal Mail unveiled a broad review of its operations as it battles to cut costs after reporting a 25 percent drop in half-year profit.
Theravance (TBPH) doses the first patient in a phase I study on novel JAK inhibitor, TD-8236, for treating serious respiratory diseases.